Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanate in infants at risk for exchange transfusion
NCT00115544Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2005
- Primary completion
- Jul 2006
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of stannsoporfin in neonatal hyperbilirubinemia (3 cohorts), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Reduction of serum bilirubin levels at 30 days, Need for exchange transfusion at 30 days and 1 more. Started Sep 2005; status: completed.
02
Drugs
stannsoporfin
03
Conditions
neonatal hyperbilirubinemia
Beyond the preview
Go deeper on NCT00115544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115544.